Biomarkers provide an indication of normal and abnormal behaviour at the cellular and molecular level. In cancer research we use biomarkers for diagnosis and prognosis and to predict how well a patient will respond to treatment.
Once a potential biomarker has been identified, it needs to be validated and tested. Biomarker research at The Kinghorn Cancer Centre focuses on biomarker identification via the “polyomics” approached outlined above, followed by development through validation and implementation as outlined in the NCI Roadmap for Biomarker Development and Qualification.
Find out more about our researchers’ research by clicking on their profiles listed on our Research Staff page.